Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

NCT04384692 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT04384692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04384692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 18, 2020
Completion date
April 23, 2030
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary myelofibrosis, secondary myelofibrosis